Nivolumab Plus Relatlimab and Gemcitabine/Cisplatin as First-Line Treatment in Advanced Biliary Tract Cancer.

NCT07369791 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Advanced Biliary Tract Cancer(BTC)

Interventions

DRUG: Nivolumab
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Nivolumab/Relatlimab

Sponsor

National Health Research Institutes, Taiwan

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]